Women aged 40 and older with node-positive early breast cancer, a group traditionally routed straight to chemotherapy, may now have a reliable way to avoid it. The OPTIMA trial, a randomised study run across NHS sites and funded by the NIHR, used the Prosigna genomic assay to sort patients by molecular risk score. Roughly two-thirds of those tested scored low enough to skip chemotherapy entirely and receive hormone therapy alone, with outcomes that trial leaders described as preserved. The results land as oncology teams across the United Kingdom and beyond grapple with how to reduce treatment toxicity without sacrificing survival.
Why Prosigna results in node-positive breast cancer matter right now
For decades, the default for women diagnosed with lymph-node-positive or high-grade early breast cancer has been adjuvant chemotherapy. The drugs work, but they carry side effects ranging from nausea and immune suppression to lasting cardiac and neurological damage. If a genomic test can reliably identify which patients will do just as well without those drugs, the clinical calculus shifts sharply. That is the promise the OPTIMA trial set out to test, and the preliminary signal is that the Prosigna/PAM50 assay can do exactly that in a real-world NHS setting.
The trial enrolled patients aged 40 and older, a deliberate choice that excluded younger women whose tumour biology tends to be more aggressive and less hormone-driven. By focusing on this population, OPTIMA aimed to answer a narrower but highly practical question: among older patients with clinically high-risk features, how many actually carry genomically low-risk disease? The answer, based on the results released so far, is a substantial majority. That finding alone could reshape treatment planning at dozens of NHS trusts, but it also raises a less obvious concern.
Adopting Prosigna across the NHS means routing tumour samples through pathology laboratories that vary widely in staffing, equipment, and turnaround time. A hospital with a two-day genomic-result window can adjust treatment plans before a patient’s first oncology appointment. A site that takes two weeks may default to starting chemotherapy rather than waiting, especially when clinical guidelines still treat chemo as standard of care for node-positive disease. If that pattern holds, regional variation in chemo avoidance rates could end up tracking lab infrastructure rather than patient biology. The OPTIMA data do not yet address this implementation gap directly, but the trial’s launch at UCLH and other NIHR-supported sites offers a controlled environment where that question can be studied.
OPTIMA trial design and the evidence from earlier genomic-risk studies
OPTIMA did not appear in a vacuum. The trial built on its own earlier feasibility phase, a randomised study within the NHS that assessed whether personalised care guided by genomic assays could be delivered in routine practice. In that feasibility report, researchers showed that Prosigna-based risk stratification was logistically workable and that clinicians were willing to act on the scores when making treatment decisions. It also identified the uncertainties the full-scale trial needed to resolve, including whether low-risk genomic scores would hold up as reliable predictors of long-term outcomes in node-positive patients specifically.
A separate and larger body of evidence comes from the MINDACT trial, a phase 3 randomised study that used a different tool, the 70-gene signature known as MammaPrint, to guide chemotherapy decisions. In MINDACT, patients classified as clinically high-risk but genomically low-risk had excellent distant metastasis–free survival without chemotherapy, supporting the idea that molecular profiling can override traditional clinical risk markers. The updated analyses, described in a peer‑reviewed summary, include exploratory age-stratified results that are particularly relevant to women in their 40s and 50s, the same age band targeted by OPTIMA.
The conceptual overlap between the two trials is significant: both ask whether genomic signatures can safely reduce chemotherapy use in early breast cancer. Where they differ is in the specific assay used and the health-system context. OPTIMA relies on Prosigna/PAM50, a test that can be run on formalin-fixed tissue in local pathology labs, and embeds its workflows in the NHS. MINDACT used MammaPrint in a largely continental European setting, with centralised testing and longer follow-up. Together, these datasets strengthen the case that genomic risk scores can refine treatment beyond what tumour size, grade, and nodal status alone can offer.
According to the published eligibility criteria, OPTIMA enrolled patients aged 40 and older with hormone receptor–positive, HER2‑negative early breast cancer and at least one involved lymph node or other high‑risk features. The Prosigna/PAM50 assay was used to assign risk categories based on tumour gene expression. Patients whose scores fell below a predefined threshold were offered endocrine therapy alone, while those above it were offered standard chemotherapy in addition to hormone treatment. The trial’s randomised structure meant that some participants had treatment guided by the genomic score, and others followed conventional clinical assessment, allowing a direct comparison of outcomes between the two approaches and an estimate of how many women could safely avoid cytotoxic drugs.
Gaps in the OPTIMA data and what patients should watch for next
Several pieces of the picture are still missing. Full primary outcome tables, including hazard ratios and confidence intervals from the completed phase 3 cohort, are not yet widely available in the public domain. The feasibility phase and protocol information provide reassurance that the study is well designed, but they do not substitute for mature survival data. Patients and clinicians will need to see peer‑reviewed results detailing invasive disease‑free survival, distant recurrence, and overall survival before genomic-guided omission of chemotherapy can be considered fully validated for all eligible subgroups.
Another gap involves long-term toxicity and quality-of-life outcomes. One of the central promises of genomic testing is to spare patients unnecessary harm. To evaluate that promise rigorously, researchers must track not only recurrences and deaths but also late cardiac effects, neuropathy, cognitive changes, and return-to-work patterns. Early reports from OPTIMA emphasise preserved outcomes in low‑risk women who skipped chemotherapy, but granular quality-of-life data have yet to be fully reported. When those data emerge, they will help quantify the real-world trade‑offs between shorter, more aggressive regimens and longer courses of endocrine therapy alone.
There is also the question of generalisability. OPTIMA’s age cutoff at 40 means that its findings do not directly apply to younger women, whose tumours can behave more aggressively even when hormone receptor–positive. MINDACT’s exploratory age analyses suggest that genomic low risk may be reassuring even in some younger patients, but those results come from a different assay and healthcare context. Clinicians will have to be cautious about extrapolating OPTIMA’s Prosigna-based strategy beyond the population it actually studied.
From a patient’s perspective, the next milestones to watch for are publication of the main phase 3 results in a journal indexed on platforms such as PubMed-linked services, and subsequent updates to national and international treatment guidelines. Once detailed data are available, bodies that set standards for adjuvant therapy in early breast cancer will be able to decide whether Prosigna-guided care should move from an investigational option to a recommended pathway for eligible women.
In the meantime, the emerging evidence already changes the nature of the clinic-room conversation. Women over 40 with node-positive, hormone receptor–positive, HER2‑negative early breast cancer can reasonably ask whether a genomic assay such as Prosigna is appropriate for them, and what local turnaround times look like. Oncologists, for their part, will have to balance existing guideline language against the growing body of trial data suggesting that many of these patients gain little from chemotherapy. As OPTIMA’s full results are released and integrated into practice, the hope is that treatment decisions will increasingly be driven by the biology of each tumour, rather than by a one‑size‑fits‑all approach rooted in older risk models.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
